Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

LONDON and GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the second quarter ended June 30, 2025. "We are encouraged by AUCATZYL's early launch performance in the U.S., driven by physician enthusiasm for the product profile, unmet need for r/r B-All patients and favorable ma ...